X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs CIPLA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA CIPLA GLENMARK PHARMA/
CIPLA
 
P/E (TTM) x 14.2 45.5 31.3% View Chart
P/BV x 4.0 3.7 106.4% View Chart
Dividend Yield % 0.3 0.3 93.0%  

Financials

 GLENMARK PHARMA   CIPLA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-16
CIPLA
Mar-17
GLENMARK PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,262622 202.9%   
Low Rs672458 146.5%   
Sales per share (Unadj.) Rs270.6181.9 148.8%  
Earnings per share (Unadj.) Rs24.912.9 193.3%  
Cash flow per share (Unadj.) Rs34.429.3 117.4%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.20.4 55.9%  
Book value per share (Unadj.) Rs151.3155.7 97.2%  
Shares outstanding (eoy) m282.16804.51 35.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.63.0 120.3%   
Avg P/E ratio x38.942.0 92.6%  
P/CF ratio (eoy) x28.118.4 152.5%  
Price / Book Value ratio x6.43.5 184.1%  
Dividend payout %8.015.5 51.7%   
Avg Mkt Cap Rs m272,778434,516 62.8%   
No. of employees `00010.023.0 43.5%   
Total wages/salary Rs m13,78226,338 52.3%   
Avg. sales/employee Rs Th7,614.96,349.1 119.9%   
Avg. wages/employee Rs Th1,374.81,143.0 120.3%   
Avg. net profit/employee Rs Th700.2449.3 155.8%   
INCOME DATA
Net Sales Rs m76,340146,302 52.2%  
Other income Rs m3562,287 15.6%   
Total revenues Rs m76,696148,589 51.6%   
Gross profit Rs m14,17224,758 57.2%  
Depreciation Rs m2,69113,229 20.3%   
Interest Rs m1,7891,594 112.2%   
Profit before tax Rs m10,04812,222 82.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,0281,798 168.5%   
Profit after tax Rs m7,01910,354 67.8%  
Gross profit margin %18.616.9 109.7%  
Effective tax rate %30.114.7 204.9%   
Net profit margin %9.27.1 129.9%  
BALANCE SHEET DATA
Current assets Rs m59,09687,370 67.6%   
Current liabilities Rs m40,01833,081 121.0%   
Net working cap to sales %25.037.1 67.3%  
Current ratio x1.52.6 55.9%  
Inventory Days Days7587 86.2%  
Debtors Days Days11962 191.3%  
Net fixed assets Rs m39,075111,567 35.0%   
Share capital Rs m2821,609 17.5%   
"Free" reserves Rs m30,281123,645 24.5%   
Net worth Rs m42,703125,254 34.1%   
Long term debt Rs m24,87336,454 68.2%   
Total assets Rs m111,026209,532 53.0%  
Interest coverage x6.68.7 76.3%   
Debt to equity ratio x0.60.3 200.1%  
Sales to assets ratio x0.70.7 98.5%   
Return on assets %7.95.7 139.1%  
Return on equity %16.48.3 198.8%  
Return on capital %17.58.5 206.1%  
Exports to sales %43.334.2 126.5%   
Imports to sales %7.48.3 89.1%   
Exports (fob) Rs m33,04450,050 66.0%   
Imports (cif) Rs m5,67212,203 46.5%   
Fx inflow Rs m36,94551,066 72.3%   
Fx outflow Rs m61,06617,678 345.4%   
Net fx Rs m-24,12233,388 -72.2%   
CASH FLOW
From Operations Rs m3,44923,824 14.5%  
From Investments Rs m-8,802-13,127 67.1%  
From Financial Activity Rs m6,986-13,239 -52.8%  
Net Cashflow Rs m934-2,478 -37.7%  

Share Holding

Indian Promoters % 48.3 16.0 301.9%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 6.9 12.2 56.6%  
FIIs % 34.4 23.7 145.1%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.5 26.2 40.1%  
Shareholders   56,727 161,166 35.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT LTD.  ABBOTT INDIA  PLETHICO PHARMA  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week; Realty & Metal Stocks Plunge(Closing)

Indian share markets continued to languish in red in the afternoon session as rupee hit its weakest point since early April amid concerns.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)

Sep 11, 2017

The question is, whether real estate buyers are financial creditors or not.

Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)

Sep 13, 2017

Nifty is above 10,000 once again. Have you missed the bus?

Rule-Based Investing Can Make A Lot of Money(The 5 Minute Wrapup)

Sep 16, 2017

We take a glimpse of Equitymaster's results from rule based investing.

Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments

Sep 18, 2017

Welcome to a bold, new initiative designed for the truly contrarian investor.

How To Link Aadhaar With Your Mutual Fund Investments(Outside View)

Sep 11, 2017

The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Sep 22, 2017 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS